The mTOR inhibitors temsirolimus and everolimus were the first to enter clinical practice in the treatment of advanced renal cell cancer, with indications later expanding to include ER+ HER2-negative (HER2−) breast cancer, pancreatic neuroendocrine tumors, and astrocytomas [121–124]. Here, ERBB2 is linked to breast cancer.